Ambalal Sarabhai Enterprises Ltd vs Novartis India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Ambalal Sarabhai Enterprises Ltd is ₹ 31.26 as of 18 May 15:30 . The P/E Ratio of Ambalal Sarabhai Enterprises Ltd changed from 4.6 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 64.14% over 5 yearsThe P/E Ratio of Novartis India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Ambalal Sarabhai Enterprises Ltd changed from ₹ 135.26 crore on March 2021 to ₹ 268.6 crore on March 2025 . This represents a CAGR of 14.71% over 5 yearsThe Market Cap of Novartis India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Ambalal Sarabhai Enterprises Ltd for the Dec '25 is ₹ 54.76 crore as compare to the Sep '25 revenue of ₹ 46.07 crore. This represent the growth of 18.86% The revenue of Novartis India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Ambalal Sarabhai Enterprises Ltd for the Dec '25 is ₹ 6.02 crore as compare to the Sep '25 ebitda of ₹ 1.98 crore. This represent the growth of 204.04% The ebitda of Novartis India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Ambalal Sarabhai Enterprises Ltd changed from ₹ 0.35 crore to ₹ 3.64 crore over 7 quarters. This represents a CAGR of 281.21% The net profit of Novartis India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Ambalal Sarabhai Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Novartis India Ltd changed from 118.09 % on March 2021 to 61.15 % on March 2025 . This represents a CAGR of -12.33% over 5 years .

About Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Limited, incorporated on June 27, 1977, houses a range of companies across multi-dimensional businesses.
It is one of the oldest pharmaceutical health care companies in India, and through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally. The Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments.
Pharmaceuticals segment is engaged in manufacture of drugs and formulations.
Electronics segment is engaged in manufacture of electronics instruments and services. In 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections. During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company.

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

FAQs for the comparison of Ambalal Sarabhai Enterprises Ltd and Novartis India Ltd

Which company has a larger market capitalization, Ambalal Sarabhai Enterprises Ltd or Novartis India Ltd?

Market cap of Ambalal Sarabhai Enterprises Ltd is 239 Cr while Market cap of Novartis India Ltd is 2,914 Cr

What are the key factors driving the stock performance of Ambalal Sarabhai Enterprises Ltd and Novartis India Ltd?

The stock performance of Ambalal Sarabhai Enterprises Ltd and Novartis India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ambalal Sarabhai Enterprises Ltd and Novartis India Ltd?

As of May 18, 2026, the Ambalal Sarabhai Enterprises Ltd stock price is INR ₹31.26. On the other hand, Novartis India Ltd stock price is INR ₹1180.5.

How do dividend payouts of Ambalal Sarabhai Enterprises Ltd and Novartis India Ltd compare?

To compare the dividend payouts of Ambalal Sarabhai Enterprises Ltd and Novartis India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.